PMID: 8943898Dec 1, 1996Paper

Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation

British Journal of Haematology
Y G MengW L Wong

Abstract

Thrombopoietin, the ligand for the c-mpl receptor, promotes proliferation and maturation of megakaryocytes. An ELISA using a chimaeric receptor, mpl-IgG, for capture, and rabbit antibody to thrombopoietin for detection was developed for the quantitation of thrombopoietin in human serum or plasma. This ELISA preferentially detects full-length thrombopoietin compared to the bioactive N-terminal half of the molecule which has homology to erythropoietin. Thrombopoietin was not detected (< 0.16 ng/ml) in 88/89 healthy individuals. However, elevated thrombopoietin concentrations of up to 3 ng/ml were detected in 59/63 thrombocytopenic patients, including cancer patients following chemotherapy. In cancer patients receiving chemotherapy with (n = 12) or without (n = 6) peripheral blood progenitor cell transplantation, thrombopoietin concentrations varied inversely with platelet counts throughout the treatment period. In general, patients who received myeloablative chemotherapy on days -7 to -2 and peripheral blood progenitor cell transplantation on day 0 had high thrombopoietin levels (0.6-2.9 ng/ml) around day 5. Low platelet counts (< 20 x 10(9)/l) occurred between days 4 and 9. Patients who received high-dose chemotherapy on day 1 (...Continue Reading

Citations

Oct 31, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M Peck-RadosavljevicP Ferenci
Oct 31, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T G Martin, M A Shuman
Aug 3, 1999·The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi·K IshidaR Nakamura
Jan 8, 1999·Veterinary Immunology and Immunopathology·H MatsushiroA Hasegawa
Apr 24, 2001·Transfusion·C C FolmanA E von dem Borne
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A BjerreP Brandtzaeg
Apr 7, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Kousaku MatsubaraHiroshi Miyazaki
Oct 30, 1998·Journal of Gastroenterology and Hepatology·T IshikawaH Asakura
Jun 3, 1999·British Journal of Haematology·C EngelS Schmitz
Apr 29, 2003·British Journal of Haematology·Erim Van OsGijsbert Van Willigen
Mar 6, 1998·British Journal of Haematology·N MiuraH Niimi
Jan 1, 1998·Hematology·R Manley, M F Murphy
Jul 28, 2001·European Journal of Gastroenterology & Hepatology·W Jelkmann
Jun 3, 2005·The American Journal of Gastroenterology·Raquel RiosJesus Prieto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.